Atossa Therapeutics

NAQ:ATOS · US04962H5063

BiotechnologyX-Small

360° View

Value34

Price/Sales—

Price/Earnings12

Price/Book88

Dividend Yield1

Growth46

Revenue Growth—

Profit Growth84

Capital Growth65

TSR 52w6

Safety84

Leverage94

Liquidity83

Refinancing18

Combined57

Sentiment19

Analyst Opinions39

Pro Holdings19

Opinion Changes50

Market Pulse29

Profile

CountryUSA

IndustryBiotechnology

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Founded2009

Websiteatossatherapeutics.com

ISINUS04962H5063

Last UpdateApr 2, 2026

Index & Theme

OncologyGeneticsBiotechnologyClinical TrialsHealth CareTherapeutics

Description

Atossa Therapeutics, Inc. (Atossa), a clinical-stage biopharmaceutical company, develops proprietary innovative medicines in areas of significant unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. The c…

Analysis

Atossa Therapeutics's 360° View rank of 45 places it below its peer average — better than 45% of its true peers.

It's growing slowly (46) and on the expensive side (34). On safety it is very well financed (84), and the market shows skeptical sentiment (19). Taken together, its Combined rank of 57 reads as above its peer average.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Atossa Therapeutics with its peers

Anixa Biosciences

NAQ:ANIX

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Sagimet Biosciences

NMQ:SGMT

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Dogwood Therapeutics

NAQ:DWTX

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

RAPT Therapeutics

NMQ:RAPT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Mineralys Therapeutics

NSQ:MLYS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Natera

NSQ:NTRA

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →